Ondine Biomedical Inc (LSE:OBI) — Market Cap & Net Worth
Market Cap & Net Worth: Ondine Biomedical Inc (OBI)
Ondine Biomedical Inc (LSE:OBI) has a market capitalization of $916.61K (GBX7.53 Billion) as of June 21, 2026. Listed on the LSE stock exchange, this UK-based company holds position #30562 globally and #823 in its home market, demonstrating a 13.73% increase in market value over the past year.
Market capitalization, also known as net worth in stock markets, is calculated by multiplying Ondine Biomedical Inc's stock price GBX14.50 by its total outstanding shares 519551468 (519.55 Million). Review how much debt does Ondine Biomedical Inc carry to assess the company's total debt and financial obligations.
Ondine Biomedical Inc Market Cap History: 2021 to 2026
Ondine Biomedical Inc's market capitalization history from 2021 to 2026. Data shows change from $3.51 Million to $916.61K (-26.33% CAGR).
Index Memberships
Ondine Biomedical Inc is a constituent of 1 market index:
| Index | Total Market Cap | Weight (%) | Rank by Market Cap |
|---|---|---|---|
|
FTSE AIM All Share Index
FTAI
|
$937.70 Million | 0.10% | #167 of 722 |
Weight: Ondine Biomedical Inc's market cap as a percentage of total index value. Rank: Position among all constituents by market cap.
Ondine Biomedical Inc Market Cap to Earnings & Revenue Ratios Timeline
This chart shows how Ondine Biomedical Inc's valuation ratios have evolved. The Price to Sales (P/S) ratio compares market cap to revenue, while the Price to Earnings (P/E) ratio compares market cap to net income. Lower values may indicate a more undervalued company relative to its financial performance.
Latest Price to Sales (P/S) Ratio
0.21x
Ondine Biomedical Inc's market cap is 0.21 times its annual revenue
Latest Price to Earnings (P/E) Ratio
N/A
P/E ratio not applicable due to negative or zero earnings
What These Ratios Tell Investors:
- Price to Sales (P/S) Ratio: Shows how much investors are paying for each dollar of the company's sales. Lower P/S ratios may indicate undervaluation.
- Price to Earnings (P/E) Ratio: Shows how much investors are paying for each dollar of the company's earnings. This is one of the most common valuation metrics.
- Trends in these ratios over time can indicate changing investor sentiment about the company's future growth prospects.
- Industry comparison provides context for whether the company is valued higher or lower than peers.
| Year | Market Cap (USD) | Revenue (USD) | Net Income (USD) | P/S Ratio | P/E Ratio |
|---|---|---|---|---|---|
| 2021 | $3.51 Million | $2.57 Million | -$50.09 Million | 1.37x | N/A |
| 2022 | $1.30 Million | $638.00K | -$19.37 Million | 2.03x | N/A |
| 2023 | $553.13K | $1.20 Million | -$14.41 Million | 0.46x | N/A |
| 2024 | $553.13K | $2.05 Million | -$19.10 Million | 0.27x | N/A |
| 2025 | $553.13K | $2.65 Million | -$29.59 Million | 0.21x | N/A |
Competitor Companies of OBI by Market Capitalization
Companies near Ondine Biomedical Inc in the global market cap rankings as of June 21, 2026.
Key companies related to Ondine Biomedical Inc by market ranking:
- Vertex Pharmaceuticals Inc (NASDAQ:VRTX): Ranked #220 globally with a market cap of $110.45 Billion USD.
- Regeneron Pharmaceuticals Inc (NASDAQ:REGN): Ranked #445 globally with a market cap of $62.84 Billion USD.
- UCB SA (BR:UCB): Ranked #547 globally with a market cap of $49.68 Billion USD ( €42.50 Billion EUR).
- Argen-X (BR:ARGX): Ranked #571 globally with a market cap of $47.14 Billion USD ( €40.32 Billion EUR).
| Rank | Company | Symbol | Market Cap | Price |
|---|---|---|---|---|
| #220 | Vertex Pharmaceuticals Inc | NASDAQ:VRTX | $110.45 Billion | $451.63 |
| #445 | Regeneron Pharmaceuticals Inc | NASDAQ:REGN | $62.84 Billion | $609.94 |
| #547 | UCB SA | BR:UCB | $49.68 Billion | €249.70 |
| #571 | Argen-X | BR:ARGX | $47.14 Billion | €773.80 |
Ondine Biomedical Inc Historical Marketcap From 2021 to 2026
Between 2021 and today, Ondine Biomedical Inc's market cap moved from $3.51 Million to $ 916.61K, with a yearly change of -26.33%.
| Year | Market Cap | Change (%) |
|---|---|---|
| 2026 | GBX916.61K | +65.71% |
| 2025 | GBX553.13K | 0.00% |
| 2024 | GBX553.13K | 0.00% |
| 2023 | GBX553.13K | -57.32% |
| 2022 | GBX1.30 Million | -63.06% |
| 2021 | GBX3.51 Million | -- |
End of Day Market Cap According to Different Sources
On Jun 21st, 2026 the market cap of Ondine Biomedical Inc was reported to be:
| Source | Market Cap |
|---|---|
| Yahoo Finance | $916.61K USD |
| MoneyControl | $916.61K USD |
| MarketWatch | $916.61K USD |
| marketcap.company | $916.61K USD |
| Reuters | $916.61K USD |
Market cap values may vary slightly between sources due to differences in calculation methods, timing, and data refresh rates.
About Ondine Biomedical Inc
Ondine Biomedical Inc., a life-sciences company, engages in the development and commercialization of antimicrobial therapies in Canada and internationally. Its primary product is Steriwave, which enables rapid elimination of pathogens associated with healthcare-associated infections. In addition, the company offers a pipeline of products for various indications, including burns, ventilator tube, … Read more